-
Product Insights
Verona Biomass Power Plant
Verona Biomass Power Plant is a biopower project located in Veneto, Italy. The project is owned by AGSM Verona SpA. The project came online in 1992. Empower your strategies with our Verona Biomass Power Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed...
-
Product Insights
NewNet Present Value Model: Verona Pharma Plc’s Ensifentrine
Empower your strategies with our Net Present Value Model: Verona Pharma Plc's Ensifentrine report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ensifentrine in Chronic Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ensifentrine in Chronic Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ensifentrine in Chronic Asthma Drug Details: Ensifentrine (RPL-554) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ensifentrine in Allergic Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ensifentrine in Allergic Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ensifentrine in Allergic Asthma Drug Details: Ensifentrine (RPL-554) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ensifentrine in Chronic Obstructive Pulmonary Disease (COPD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ensifentrine in Chronic Obstructive Pulmonary Disease (COPD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ensifentrine in Chronic Obstructive Pulmonary Disease (COPD) Drug Details:...
-
Product Insights
Bronchiectasis – Drugs In Development, 2023
Global Markets Direct’s, ‘Bronchiectasis - Drugs In Development, 2023’, provides an overview of the Bronchiectasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bronchiectasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Allergic Asthma – Drugs In Development, 2023
Global Markets Direct’s, ‘Allergic Asthma - Drugs In Development, 2023’, provides an overview of the Allergic Asthma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Allergic Asthma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Cystic Fibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Cystic Fibrosis - Drugs In Development, 2023’, provides an overview of the Cystic Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cystic Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ensifentrine in Cystic Fibrosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ensifentrine in Cystic Fibrosis Drug Details: Ensifentrine (RPL-554) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KVA-12123 in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. KVA-12123 in Ovarian Cancer Drug Details: KVA-12123 is under development for the treatment of solid...